You are here: Industry Insights > carcinoma

News List

FDA Approves Carcinoma Treatment americanpharmaceuticalreview
July 23, 2021
The FDA approved pembrolizumab (Keytruda - Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) ...
FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma drugs
September 23, 2019
Merck, known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the combination of Keytruda ...
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma drugs
May 17, 2019
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma.
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma drugs
May 15, 2019
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma.
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer pharmafiles
April 24, 2019
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination with Pfizer’s Inlyta (axitinib) in advanced renal cell carcinoma.
Moleculin Announces Significant Discovery in Lung Cancer Models americanpharmaceuticalreview
April 22, 2019
Moleculin Announces Significant Discovery in Lung Cancer Models...
FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma americanpharmaceuticalreview
November 14, 2018
FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma
Korea approves Opdivo-Yervoy for renal cell carcinoma treatment biospectrumasia
September 29, 2018
The approval is based on a clinical trial called CheckMate-214.
Anticancer Agent LENVIMA® Approved for Additional Indication of Unresectable Hepatocellular Carcinoma in Japan, First Approval Worldwide for LENVIMA for HCC biospace
March 26, 2018
Eisai Company, Ltd. and Merck & Company today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA® has been approved in Japan for unresectable hepatocellular carcinoma